Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
4,973
archived clinical trials in
High Cholesterol

Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated:  2/1/2018
Stanford University
mi
from
Stanford, CA
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated: 2/1/2018
Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated:  2/1/2018
University of Colorado
mi
from
Aurora, CO
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated: 2/1/2018
University of Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated:  2/1/2018
University of Chicago
mi
from
Chicago, IL
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated: 2/1/2018
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated:  2/1/2018
Johns Hopkins University
mi
from
Baltimore, MD
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated: 2/1/2018
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated:  2/1/2018
Brigham and Women's Hosp
mi
from
Boston, MA
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated: 2/1/2018
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated:  2/1/2018
Children's Hospital Boston
mi
from
Boston, MA
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated: 2/1/2018
Children's Hospital Boston
mi
from
Boston, MA
Click here to add this to my saved trials
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated:  2/1/2018
University of Michigan
mi
from
Ann Arbor, MI
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated: 2/1/2018
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated:  2/1/2018
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated: 2/1/2018
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated:  2/1/2018
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated: 2/1/2018
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated:  2/1/2018
Univ of Pennsylvania
mi
from
Philadelphia, PA
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated: 2/1/2018
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated:  2/1/2018
Vanderbilt University
mi
from
Nashville, TN
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated: 2/1/2018
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated:  2/1/2018
Toronto General Hospital
mi
from
Toronto,
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated: 2/1/2018
Toronto General Hospital
mi
from
Toronto,
Click here to add this to my saved trials
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated:  2/1/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated: 2/1/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated:  2/1/2018
Cinncinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Enrolling
Updated: 2/1/2018
Cinncinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)
Genotoxic Stress, Atherosclerosis, and Metabolic Syndrome-AIM 2
Status: Enrolling
Updated:  2/2/2018
Washington University in St. Louis
mi
from
Saint Louis, MO
Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)
Genotoxic Stress, Atherosclerosis, and Metabolic Syndrome-AIM 2
Status: Enrolling
Updated: 2/2/2018
Washington University in St. Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Atheroma Reduction With Chloroquine in Patients With the Metabolic Syndrome (ARCH-MS)
Genotoxic Stress, Atherosclerosis, and Metabolic Syndrome- Aim 3
Status: Enrolling
Updated:  2/2/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Atheroma Reduction With Chloroquine in Patients With the Metabolic Syndrome (ARCH-MS)
Genotoxic Stress, Atherosclerosis, and Metabolic Syndrome- Aim 3
Status: Enrolling
Updated: 2/2/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 (SAR236553) in Patients With Hypercholesterolemia
A Phase 2, Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 Administered by Subcutaneous Injection in Patients With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated:  2/4/2018
Clinical Research Facility
mi
from
Mission Viejo, CA
Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 (SAR236553) in Patients With Hypercholesterolemia
A Phase 2, Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 Administered by Subcutaneous Injection in Patients With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated: 2/4/2018
Clinical Research Facility
mi
from
Mission Viejo, CA
Click here to add this to my saved trials
Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 (SAR236553) in Patients With Hypercholesterolemia
A Phase 2, Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 Administered by Subcutaneous Injection in Patients With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated:  2/4/2018
Clinical Research Facility
mi
from
Newport Beach, CA
Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 (SAR236553) in Patients With Hypercholesterolemia
A Phase 2, Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 Administered by Subcutaneous Injection in Patients With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated: 2/4/2018
Clinical Research Facility
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 (SAR236553) in Patients With Hypercholesterolemia
A Phase 2, Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 Administered by Subcutaneous Injection in Patients With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated:  2/4/2018
Clinical Research Facility
mi
from
Thousand Oaks, CA
Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 (SAR236553) in Patients With Hypercholesterolemia
A Phase 2, Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 Administered by Subcutaneous Injection in Patients With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated: 2/4/2018
Clinical Research Facility
mi
from
Thousand Oaks, CA
Click here to add this to my saved trials
Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 (SAR236553) in Patients With Hypercholesterolemia
A Phase 2, Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 Administered by Subcutaneous Injection in Patients With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated:  2/4/2018
Clinical Research Facility
mi
from
Miami, FL
Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 (SAR236553) in Patients With Hypercholesterolemia
A Phase 2, Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 Administered by Subcutaneous Injection in Patients With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated: 2/4/2018
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 (SAR236553) in Patients With Hypercholesterolemia
A Phase 2, Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 Administered by Subcutaneous Injection in Patients With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated:  2/4/2018
Clinical Research Facility
mi
from
Port Orange, FL
Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 (SAR236553) in Patients With Hypercholesterolemia
A Phase 2, Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 Administered by Subcutaneous Injection in Patients With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated: 2/4/2018
Clinical Research Facility
mi
from
Port Orange, FL
Click here to add this to my saved trials
Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 (SAR236553) in Patients With Hypercholesterolemia
A Phase 2, Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 Administered by Subcutaneous Injection in Patients With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated:  2/4/2018
Clinical Research Facility
mi
from
Kansas City, KA
Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 (SAR236553) in Patients With Hypercholesterolemia
A Phase 2, Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 Administered by Subcutaneous Injection in Patients With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated: 2/4/2018
Clinical Research Facility
mi
from
Kansas City, KA
Click here to add this to my saved trials
Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 (SAR236553) in Patients With Hypercholesterolemia
A Phase 2, Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 Administered by Subcutaneous Injection in Patients With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated:  2/4/2018
Clinical Research Facility
mi
from
Auburn, ME
Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 (SAR236553) in Patients With Hypercholesterolemia
A Phase 2, Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 Administered by Subcutaneous Injection in Patients With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated: 2/4/2018
Clinical Research Facility
mi
from
Auburn, ME
Click here to add this to my saved trials
Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 (SAR236553) in Patients With Hypercholesterolemia
A Phase 2, Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 Administered by Subcutaneous Injection in Patients With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated:  2/4/2018
Clinical Research Facility
mi
from
Durham, NC
Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 (SAR236553) in Patients With Hypercholesterolemia
A Phase 2, Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 Administered by Subcutaneous Injection in Patients With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated: 2/4/2018
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 (SAR236553) in Patients With Hypercholesterolemia
A Phase 2, Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 Administered by Subcutaneous Injection in Patients With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated:  2/4/2018
Clinical Research Facility
mi
from
Houston, TX
Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 (SAR236553) in Patients With Hypercholesterolemia
A Phase 2, Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 Administered by Subcutaneous Injection in Patients With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated: 2/4/2018
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 (SAR236553) in Patients With Hypercholesterolemia
A Phase 2, Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 Administered by Subcutaneous Injection in Patients With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated:  2/4/2018
mi
from
Chicoutimi,
Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 (SAR236553) in Patients With Hypercholesterolemia
A Phase 2, Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 Administered by Subcutaneous Injection in Patients With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated: 2/4/2018
mi
from
Chicoutimi,
Click here to add this to my saved trials
Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 (SAR236553) in Patients With Hypercholesterolemia
A Phase 2, Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 Administered by Subcutaneous Injection in Patients With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated:  2/4/2018
Clinical Research Facility
mi
from
Saint Louis, MO
Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 (SAR236553) in Patients With Hypercholesterolemia
A Phase 2, Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 Administered by Subcutaneous Injection in Patients With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated: 2/4/2018
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 (SAR236553) in Patients With Hypercholesterolemia
A Phase 2, Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 Administered by Subcutaneous Injection in Patients With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated:  2/4/2018
Clinical Research Facility
mi
from
Cincinnati, OH
Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 (SAR236553) in Patients With Hypercholesterolemia
A Phase 2, Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 Administered by Subcutaneous Injection in Patients With Heterozygous Familial Hypercholesterolemia
Status: Enrolling
Updated: 2/4/2018
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
Jacksonville Center for Clinical Research
mi
from
Jacksonville, FL
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
Jacksonville Center for Clinical Research
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
Appalachian Research Associates
mi
from
Fort Payne, AL
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
Appalachian Research Associates
mi
from
Fort Payne, AL
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
Del Sol Research Mangagement, LLC
mi
from
Tucson, AZ
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
Del Sol Research Mangagement, LLC
mi
from
Tucson, AZ
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
Westside Medical Associates of Los Angeles
mi
from
Beverly Hills, CA
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
Westside Medical Associates of Los Angeles
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
Hope Clinical Research, LLC
mi
from
Canoga Park, CA
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
Hope Clinical Research, LLC
mi
from
Canoga Park, CA
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
Sc Clinical Research, Inc.
mi
from
Garden Grove, CA
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
Sc Clinical Research, Inc.
mi
from
Garden Grove, CA
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
National Research Institute
mi
from
Huntington Park, CA
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
National Research Institute
mi
from
Huntington Park, CA
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
National Research Institute
mi
from
Los Angeles, CA
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
National Research Institute
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
Paradigm Clinical Research
mi
from
San Diego, CA
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
Paradigm Clinical Research
mi
from
San Diego, CA
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
Paradigm Research
mi
from
Wheat Ridge, CO
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
Paradigm Research
mi
from
Wheat Ridge, CO
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
Excel Medical Research
mi
from
Boca Raton, FL
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
Excel Medical Research
mi
from
Boca Raton, FL
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
Meridien Research
mi
from
Bradenton, FL
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
Meridien Research
mi
from
Bradenton, FL
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
Direct Helpers Research Center
mi
from
Hialeah, FL
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
Direct Helpers Research Center
mi
from
Hialeah, FL
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
Indago Research & Health Center, Inc.
mi
from
Hialeah, FL
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
Indago Research & Health Center, Inc.
mi
from
Hialeah, FL
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
Sunrise Medical Research
mi
from
Lauderdale Lakes, FL
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
Sunrise Medical Research
mi
from
Lauderdale Lakes, FL
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
AR Developoment Solutions
mi
from
Miami Lakes, FL
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
AR Developoment Solutions
mi
from
Miami Lakes, FL
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
San Marcus Research Clinic
mi
from
Miami, FL
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
San Marcus Research Clinic
mi
from
Miami, FL
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
Millenium Clinical Research
mi
from
Miami, FL
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
Millenium Clinical Research
mi
from
Miami, FL
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
Medcare Research
mi
from
Miami, FL
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
Medcare Research
mi
from
Miami, FL
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
Soma Medical Research
mi
from
West Palm Beach, FL
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
Soma Medical Research
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
Evanston Premier Clinical Research
mi
from
Evanston, IL
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
Evanston Premier Clinical Research
mi
from
Evanston, IL
Click here to add this to my saved trials
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated:  2/12/2018
Midwest Institute for Clinical Research
mi
from
Indianapolis, IN
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)
Status: Enrolling
Updated: 2/12/2018
Midwest Institute for Clinical Research
mi
from
Indianapolis, IN
Click here to add this to my saved trials